Serum CD93 as a Potential Diagnostic Biomarker for Endometrial Cancer: A Case–Control Study
Journal of Clinical Medicine · 29.04.2026 · 15 (9) · 3409
DOI: 10.3390/jcm15093409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.04.2026. Verfasst von İsmail Bağlar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, 34865 Istanbul, Türkiye. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
CD93, an angiogenesis-related transmembrane glycoprotein, is transcriptomically downregulated in uterine corpus endometrial carcinoma, yet circulating protein levels have not been clinically evaluated. This study aimed to evaluate serum CD93 as a diagnostic biomarker for EC and to examine its association with clinicopathological parameters.
Methods
In this single-center case–control study, serum CD93 concentrations were measured by enzyme-linked immunosorbent assay in 46 patients with histologically confirmed primary EC and 35 controls with histologically verified benign gynecological pathology. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed.
Results
Serum CD93 was significantly lower in EC patients than controls (median 4.55 [IQR 3.51–6.97] vs. 10.24 [7.18–12.14] ng/mL; p < 0.001). In multivariable analysis adjusted for age and body mass index, lower CD93 remained independently associated with EC (OR = 0.521; 95% CI 0.061–0.720; p < 0.001). ROC analysis yielded an area under the curve of 0.845 (95% CI 0.759–0.921), with 82.6% sensitivity and 74.3% specificity at a cut-off of 7.338 ng/mL. CD93 levels showed no significant association with histological subtype, grade, lymphovascular space invasion, nodal metastasis, or recurrence.
Conclusions
Serum CD93 is significantly reduced in EC and demonstrates independent diagnostic performance, supporting its prospective validation as a non-invasive biomarker in larger multicenter cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, 34865 Istanbul, Türkiye.
- Department of Gynecologic Oncology, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, 34865 Istanbul, Türkiye.
- Management Department, Business School, Ankara Yildirim Beyazit University, 06010 Ankara, Türkiye.
- Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, 34408 Istanbul, Türkiye.
ORCID-Profile: İsmail Bağlar, Fatih Şanlıkan, Esra Keles, Sahra Sultan Kara, Cansu Ergenç Özdaş, Hafize Uzun
Zitieren
APA
Bağlar, İ., Şanlıkan, F., Keles, E., Kara, S. S., Özdaş, C. E., Dönmez, Y. Ç., & Uzun, H. (2026). Serum CD93 as a Potential Diagnostic Biomarker for Endometrial Cancer: A Case–Control Study. Journal of Clinical Medicine, 15(9), 3409. https://doi.org/10.3390/jcm15093409
Vancouver
Bağlar İ, Şanlıkan F, Keles E, Kara SS, Özdaş CE, Dönmez YÇ, et al. Serum CD93 as a Potential Diagnostic Biomarker for Endometrial Cancer: A Case–Control Study. Journal of Clinical Medicine. 2026;15(9):3409. doi:10.3390/jcm15093409
BibTeX
@article{Balar2026,
author = {Bağlar, İsmail and Şanlıkan, Fatih and Keles, Esra and Kara, Sahra Sultan and Özdaş, Cansu Ergenç and Dönmez, Yeliz Çeçen and Uzun, Hafize},
title = {Serum CD93 as a Potential Diagnostic Biomarker for Endometrial Cancer: A Case–Control Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {9},
pages = {3409},
doi = {10.3390/jcm15093409}
}
EUVIMED